ESPOO, Finland, May 21, 2026
Orion Pharma announced that it will present the first clinical data from its ongoing Phase 1/2 TEADES trial evaluating ODM-212, an investigational oral pan-TEAD inhibitor, at the upcoming ASCO Annual Meeting 2026. The presentation marks a significant milestone for Orion’s oncology pipeline as the company advances a new targeted therapy approach focused on the Hippo signaling pathway, an important cancer-driving mechanism linked to aggressive tumor growth and treatment resistance. The TEADES study is currently evaluating ODM-212 in patients with advanced solid tumors, particularly cancers associated with dysregulation of the Hippo pathway, including malignant pleural mesothelioma (MPM) and epithelioid hemangioendothelioma (EHE).
ODM-212 is an investigational oral small-molecule pan-TEAD inhibitor designed to block the activity of TEAD transcription factors involved in the Hippo signaling pathway. Dysregulation of this pathway, especially through abnormal activation of YAP and TAZ proteins, is known to contribute to uncontrolled tumor proliferation, metastasis, and resistance to conventional cancer therapies. Orion stated that ODM-212 works by disrupting YAP-TEAD protein interactions and inhibiting TEAD auto-palmitoylation, a process considered essential for TEAD activation and downstream cancer signaling. The company believes this mechanism could create a new treatment strategy for patients with difficult-to-treat cancers where current therapies provide limited benefit.
TEADES Trial Evaluates ODM-212 Across Advanced Solid Tumors
The ongoing TEADES trial is a global, multi-center, open-label Phase 1/2 study expected to enroll up to 300 patients across leading oncology centers in the United States and Europe. The study focuses on patients with advanced solid tumors who have progressed despite available standard therapies and who have limited remaining treatment options. Primary objectives of the trial include evaluating the safety, tolerability, and dose optimization of ODM-212, while secondary endpoints include overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Orion is also exploring the broader potential of ODM-212 across multiple tumor types characterized by Hippo pathway dysfunction.
The first clinical findings from the Phase 1 portion of the TEADES study will be presented during the Developmental Therapeutics session at ASCO 2026 under Abstract #3111. According to Orion executives, the presentation represents the company’s first opportunity to publicly share human clinical data for ODM-212 since entering clinical development. Professor Outi Vaarala, Executive Vice President of Research & Development at Orion Pharma, stated that the upcoming ASCO presentation is an important milestone for the company’s clinical-stage TEAD inhibitor program and will help guide future development strategies for patients with high unmet medical need in advanced oncology settings.
Targeting the Hippo Pathway Emerges as a New Oncology Frontier
Advertisement
The Hippo signaling pathway has become an increasingly important focus in oncology research because of its central role in regulating cell growth, organ size, tissue regeneration, and tumor suppression. When the pathway becomes dysregulated, abnormal YAP/TAZ activation can drive aggressive tumor growth and contribute to resistance against chemotherapy, immunotherapy, and targeted treatments. Despite growing scientific interest, TEAD-targeted therapies remain an emerging area with relatively few clinical-stage programs globally. Orion’s ODM-212 therefore represents one of the more closely watched investigational agents in this developing therapeutic category.
Orion is simultaneously advancing broader clinical development efforts through both the TEADES and TEADCO programs, evaluating ODM-212 as both a standalone therapy and in combination with existing standard-of-care treatments across multiple solid tumors. The company believes combination approaches could eventually enhance treatment responses and overcome resistance mechanisms in difficult cancers. As precision oncology increasingly shifts toward pathway-driven therapies, successful development of TEAD inhibitors may open a new class of targeted medicines capable of addressing cancers with limited therapeutic options today.
The presentation at ASCO 2026 places Orion Pharma among a growing group of biotechnology and pharmaceutical companies investing in next-generation targeted oncology platforms. With increasing industry attention on the Hippo pathway and TEAD biology, positive early clinical data from ODM-212 could significantly strengthen Orion’s position in the competitive solid tumor oncology market while expanding future partnership and development opportunities in precision cancer therapeutics.
Source: Orion Pharma press release
